Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Assessment of the Sublingual Microcirculation with the GlycoCheck System: Reproducibility and Examination Conditions

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Individual Effects of Liraglutide on Cardiorenal Risk Markers: Results from the LEADER Trial

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Lipoprotein(a) and Decline in Renal Function, Incidence of Cardiovascular Disease, and Mortality in Individuals with Type 2 Diabetes and Microalbuminuria

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  • Daniël H van Raalte
  • Petter Bjornstad
  • Frederik Persson
  • David R Powell
  • Rita de Cassia Castro
  • Ping Stella Wang
  • Minzhi Liu
  • Hiddo J L Heerspink
  • David Cherney
View graph of relations

Objective: In people with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular risk and progression of diabetic kidney disease. Our aim was to determine whether sotagliflozin (SOTA), a dual SGLT1i and SGLT2i, had favorable effects on clinical biomarkers suggestive of kidney protection in adults with type 1 diabetes. Research Design and Methods: In this 52-week pooled analysis, 1,575 adults enrolled in the inTandem1 and inTandem2 trials were randomized to SOTA 200 mg, 400 mg, or placebo in addition to optimized insulin therapy. Changes in cardiorenal biomarkers were assessed. Results: At 52 weeks, in response to SOTA 200 and 400 mg, the placebo-corrected least squares mean change from baseline in estimated glomerular filtration rate was -2.0 mL/min/1.73 m 2 (P = 0.010) and -0.5 mL/min/1.73 m 2 (P = 0.52), respectively. Systolic blood pressure difference was -2.9 and -3.6 mmHg (P < 0.0001 for both); diastolic blood pressure changed by -1.4 (P = 0.0033) and -1.6 mmHg (P = 0.0008). In participants with baseline urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g, UACR decreased by 23.7% (P = 0.054) and 18.3% (P = 0.18) for SOTA 200 and SOTA 400 mg, respectively, versus placebo. Increases in serum albumin and hematocrit and reductions in uric acid were observed throughout 52 weeks with both SOTA doses. Conclusions: SOTA was associated with short- and long-term renal hemodynamic changes, which were similar to those seen with SGLT2i in type 2 diabetes. Further investigation around cardiorenal effects of SOTA in people with type 1 diabetes is justified.

Original languageEnglish
JournalDiabetes Care
Volume42
Issue number10
Pages (from-to)1921-1929
Number of pages9
ISSN1935-5548
DOIs
Publication statusPublished - 1 Oct 2019

ID: 57722390